glp 1 access The GLP-1 Gap: Mapping Who Can Actually Afford America's Miracle Weight-Loss Drugs Today marks the launch of
Description
[Source: Fierce Pharma ] January 2025 The FDA fast-tracked tirzepatide for cardiovascular risk reduction in obesity patients, following landmark trial results showing significant benefit beyond weight loss
What changed FDA officially removed semaglutide from the drug shortage list in early 2025, declaring that supply had caught up with demand
This suggests that the GLP1/GIP pathway can increase efficacy over GLP-1RAs [99]
The Journal of Endocrinology
1.7% vs 1.0%point), respectively
Semaglutide (Ozempic, Wegovy): Clinicians use Ozempic to treat diabetes, and Wegovy for weight loss
